Spots Global Cancer Trial Database for inflammatory myofibroblastic tumors
Every month we try and update this database with for inflammatory myofibroblastic tumors cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
---|---|---|---|---|---|---|
Pharmacokinetics, Safety, and Efficacy of Brigatinib Monotherapy in Pediatric and Young Adult Participants With ALK+ Anaplastic Large Cell Lymphoma, Inflammatory Myofibroblastic Tumors or Other Solid Tumors | NCT04260009 | Anaplastic Lymp... Inflammatory My... Solid Tumors | Brigatinib Brigatinib AAF | 1 Year - 25 Years | Takeda | |
Phase 1/2 Study of X-396, an Oral ALK Inhibitor, in Patients With ALK-positive Non-Small Cell Lung Cancer | NCT01625234 | Advanced Solid ... Non-small Cell ... | Phase I: X-396 ... Phase II: X-396... | 18 Years - | Xcovery Holdings, Inc. | |
Phase 1/2 Study of X-396, an Oral ALK Inhibitor, in Patients With ALK-positive Non-Small Cell Lung Cancer | NCT01625234 | Advanced Solid ... Non-small Cell ... | Phase I: X-396 ... Phase II: X-396... | 18 Years - | Xcovery Holdings, Inc. |